RGEN

Repligen

• Simply Wall St·1d ago

  Repligen (RGEN) Trades At A 2% Premium After Board Retirement Update

• NASDAQ·5d ago

  Notable Monday Option Activity: RGEN, ASST, INOD

• TipRanks·09/16 09:16

  Repligen (RGEN) Gets a Buy from Stifel Nicolaus

• TipRanks·09/15 20:35

  Repligen announces long-serving director Karen Dawes’ retirement

• Simply Wall St·09/12 09:15

  Repligen (RGEN) Stock May Be Near Fair Value As Sales Premium Persists

• NASDAQ·09/10 15:42

  Roche Gets FDA Priority Tag for Enspryng in Rare Autoimmune Disorder

• NASDAQ·09/09 18:47

  Novartis' Del-desiran Fails Late-Stage DM1 Study, Shares Fall

• Dow Jones·09/09 18:05

  Repligen Is Maintained at Buy by UBS

• Dow Jones·09/09 18:05

  Repligen Price Target Raised to $225.00/Share From $195.00 by UBS

• Benzinga·09/09 17:56

  UBS Maintains Buy on Repligen, Raises Price Target to $225

• TipRanks·09/08 22:10

  Repligen clears antitrust hurdle in BioLife Solutions acquisition

• Seeking Alpha·09/04 08:40

  Software Rebound Extends Moat Index Gains

• NASDAQ·09/01 16:05

  Axsome Begins Phase III Study on AXS-05 for Smoking Cessation

• NASDAQ·09/01 16:02

  JAZZ Rises on Updated OS Results From Gastric Cancer Study

• Seeking Alpha·09/01 11:59

  William Blair updates its stock Conviction List